CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
2.590
+0.010 (0.39%)
Oct 6, 2026, 12:29 PM EDT - Market open
CytomX Therapeutics Employees
CytomX Therapeutics had 69 employees as of December 31, 2025. The number of employees decreased by 52 or -42.98% compared to the previous year.
Employees
69
Change (1Y)
-52
Growth (1Y)
-42.98%
Revenue / Employee
$265,261
Profits / Employee
-$1,197,899
Market Cap
564.36M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 69 | -52 | -42.98% | 69 | 0 |
| Dec 31, 2024 | 121 | -1 | -0.82% | 119 | 2 |
| Dec 31, 2023 | 122 | 4 | 3.39% | 120 | 2 |
| Dec 31, 2022 | 118 | -60 | -33.71% | 116 | 2 |
| Dec 31, 2021 | 178 | 32 | 21.92% | 174 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 620 |
| Phathom Pharmaceuticals | 371 |
| Capricor Therapeutics | 231 |
| CorMedix | 191 |
| Prime Medicine | 146 |
| MapLight Therapeutics | 133 |
| Zevra Therapeutics | 61 |
| Oculis Holding AG | 60 |
CTMX News
- 21 days ago - CytomX Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 27 days ago - CytomX Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 27 days ago - CytomX Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 27 days ago - CytomX Therapeutics Slides: Wells Fargo 21st Annual Healthcare Conference - Filings
- 5 weeks ago - CytomX Therapeutics to Present at Upcoming September Investor Conferences - GlobeNewsWire
- 5 weeks ago - CytomX Therapeutics gets Fast Track Designation for Varseta-M - TheFly
- 5 weeks ago - CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) - GlobeNewsWire
- 7 weeks ago - CytomX Therapeutics price target lowered to $11 from $12 at JPMorgan - TheFly